Vertex Pharmaceuticals Incorporated (VRTX) Earnings History
Annual and quarterly earnings data from 1991 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 86.2% | 39.1% | 32.9% |
| 2024 | 86.1% | -2.1% | -4.9% |
| 2023 | 87.2% | 38.8% | 36.7% |
| 2022 | 87.9% | 48.2% | 37.2% |
| 2021 | 88.1% | 36.7% | 30.9% |
Download Data
Export VRTX earnings history in CSV or JSON format
Free sign-in required to download data
Vertex Pharmaceuticals Incorporated (VRTX) Earnings Overview
As of March 1, 2026, Vertex Pharmaceuticals Incorporated (VRTX) reported trailing twelve-month net income of $3.68B, reflecting +8.4% year-over-year growth. The company earned $14.27 per diluted share over the past four quarters, with a net profit margin of 0.3%.
Looking at the long-term picture, VRTX's 5-year EPS compound annual growth rate (CAGR) stands at +8.3%, showing solid earnings momentum. The company achieved its highest annual net income of $3.95B in fiscal 2025, representing a new all-time high.
Vertex Pharmaceuticals Incorporated maintains positive profitability with a gross margin of 0.9%, operating margin of 0.4%, and net margin of 0.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), ASND (-$228M net income, -0.3% margin), BBIO (-$729M net income, -1.5% margin), VRTX has outperformed on profitability metrics. Compare VRTX vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.95B | +838.1% | $4.69B | $15.32 | 32.9% | 39.1% |
| 2024 | -$536M | -114.8% | -$233M | $-2.08 | -4.9% | -2.1% |
| 2023 | $3.62B | +9.0% | $3.83B | $13.89 | 36.7% | 38.8% |
| 2022 | $3.32B | +41.8% | $4.31B | $12.82 | 37.2% | 48.2% |
| 2021 | $2.34B | -13.6% | $2.78B | $9.01 | 30.9% | 36.7% |
| 2020 | $2.71B | +130.4% | $2.86B | $10.29 | 43.7% | 46.0% |
| 2019 | $1.18B | -43.9% | $1.20B | $4.51 | 28.3% | 28.8% |
| 2018 | $2.10B | +695.8% | $635M | $8.09 | 68.8% | 20.8% |
| 2017 | $263M | +335.1% | $123M | $1.04 | 10.6% | 5.0% |
| 2016 | -$112M | +79.9% | $10M | $-0.46 | -6.6% | 0.6% |
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRTX vs AGIO
See how VRTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VRTX growing earnings?
VRTX EPS stands at $14.27, with +8.4% growth matching the 5-year CAGR of +8.3%. TTM net income is $3.7B. Earnings trajectory remains consistent.
What are VRTX's profit margins?
Vertex Pharmaceuticals Incorporated net margin is +0.3%, with operating margin at +0.4%. Below-average margins reflect competitive or cost pressures.
How consistent are VRTX's earnings?
VRTX earnings data spans 1991-2025. The current earnings trend is +8.4% YoY. Historical data enables comparison across business cycles.